Researchers step closer to treating 'inflammatory' molecules behind diabetes, arthritis, strokes, heart disease

File: A researcher at CS/ECE wears a lab coat.
File: A researcher at CS/ECE wears a lab coat. TracerBullet999/Flickr

Researchers at Cedars-Sinai have moved a step closer to better treatment of arthritis, diabetes and a number of other diseases caused in part by inflammation, and it all starts with a tiny molecule.

The new finding may help create medications that will stop our bodies from over-producing a molecule called “interluekin-1 beta.” That molecule is a contributor to Type 2 diabetes, rheumatoid arthritis, some strokes and heart disease.

Until now, treatment focused on blocking the molecule only after our bodies created it.

But Cedars-Sinai researchers say they now have a better understanding of how the body produces the molecule in the first place — an important step toward new medications that will stop the molecule’s production before it starts, leading to better treatment of inflammatory diseases that affect an estimated 100 million Americans.

blog comments powered by Disqus